Ravi Salgia to Drug Design
This is a "connection" page, showing publications Ravi Salgia has written about Drug Design.
Connection Strength
0.271
-
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2021 01 19; 2(1):100186.
Score: 0.188
-
Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol. 2009 Apr; 36(2 Suppl 1):S52-8.
Score: 0.083